Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychological Harm in High-Fidelity Simulation: A Concept Analysis.

Nursing research and practice·2026
Same author

The Impact of High-Fidelity Simulation on Undergraduate Nursing Students' Attitudes Toward Older Adults: A Scoping Review.

Simulation in healthcare : journal of the Society for Simulation in Healthcare·2026
Same author

Nurse-Administered Screening Tools for Detecting Elder Abuse in Emergency Departments: A Scoping Review.

Journal of advanced nursing·2024
Same author

The Lived Experience of Cardiac Arrest Survivors: A Scoping Review.

The Journal of cardiovascular nursing·2024
Same author

Cardiogenic Shock: An Overview.

Critical care nursing quarterly·2024
Same author

A concurrent mixed-method study exploring the experiences of interprofessional collaboration among Canadian midwives and obstetricians.

Journal of advanced nursing·2024

Related Experiment Video

Updated: May 29, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

Hypertensive Acute Heart Failure: An Evidence Based Approach.

Mohamed Toufic El Hussein1, Alyssa Homan, Joseph Osuji C

  • 1Author Affiliations: Faculty of Health, School of Nursing and Midwifery, Community & Education, Mount Royal University, Alberta, Canada; Faculty of Nursing, University of Alberta, Alberta, Canada; Acute Care Nurse Practitioner Medical Cardiology, Coronary Care Unit, Rockyview General Hospital, Alberta, Canada (Dr El Hussein); Department of Pediatrics, Alberta Health Services, Alberta, Calgary, Canada (Mrs Homan); and Faculty of Health, School of Nursing and Midwifery, Community, and Education, Mount Royal University, Calgary, AB, Canada (Dr Osuji).

Critical Care Nursing Quarterly
|May 27, 2026
PubMed
Summary

Nurse practitioners can improve hypertensive acute heart failure (H-AHF) management by prioritizing vasodilators over diuretics and using advanced therapies like sequential nephron blockade and noninvasive ventilation for better patient outcomes.

Keywords:
ACE inhibitorsSGLT2 inhibitorshypertensive acute heart failurenitratessequential nephron blockadethiazide diuretics

More Related Videos

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

Related Experiment Videos

Last Updated: May 29, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

Area of Science:

  • Cardiology
  • Nursing
  • Pharmacology

Background:

  • Hypertensive acute heart failure (H-AHF) presents unique management challenges.
  • Traditional approaches focused on volume overload may not be optimal for H-AHF.

Purpose of the Study:

  • To review current management strategies for H-AHF.
  • To provide guidance for nurse practitioners in managing H-AHF.

Main Methods:

  • Literature review of current approaches in H-AHF management.
  • Emphasis on the shift in understanding congestion causes in H-AHF.
  • Discussion of pharmacologic and non-pharmacologic interventions.

Main Results:

  • Vascular redistribution is a key factor in H-AHF congestion, suggesting vasodilators as a primary treatment.
  • Sequential nephron blockade and high-dose IV nitroglycerin show efficacy in diuretic resistance and pressure reduction.
  • Noninvasive ventilation aids respiratory recovery in acute pulmonary edema.

Conclusions:

  • Current H-AHF management strategies focus on vasodilators and advanced therapies.
  • Further research is necessary to refine safety and efficacy in various clinical settings.